Molecular Discovery Grants
**CURRENT mdg due november 20, 2020 at 5pm**
Information Sessions:
Wednesday, Oct 28, 2-3 pm
(https://msu.zoom.us/j/98037609354 Passcode: 924950)
Thursday, November 5, 2-3 pm
(https://msu.zoom.us/j/95934710957 Passcode: 384181)
The Michigan State University Molecular Discovery Grants (MSU-MDG) have been established between the Department of Pharmacology & Toxicology and MSU Drug Discovery to provide pilot funding for accelerating the discovery and development of chemical technologies with applications for human health, animal health and agricultural use (max $30,000; average: $10,000- 15,000). The primary aim of these funds is to advance projects toward extramural funding or to the creation or development of intellectual property and commercialization.
Specific goals include:
• Assisting investigators in advancing their programs in the early phases of the discovery process with long-term commercialization in mind.
• Supporting early activities (e.g. screening) not readily funded by other sources.
• Providing additional data to support extramural grant applications.
• Aiding in the discovery or development of intellectual property.
• Accelerating therapeutics or diagnostics discovery and development programs
For more information, please contact:
Joseph Nichols, PhD - MSU Drug Discovery - Project Manager
Email: nicho621@msu.edu
MDG Cycle
|
Investigator
|
Title
|
---|---|---|
2/20 | Jason Bazil, Ph.D. | The search for Novel Mitoprotectants Against Reperfusion Injury |
Bryan Copple, Ph.D. | Development of Machrphage Phenotypic Modulators as a Treatment for Liver Fibrosis | |
Sean Crosson, Ph.D. | High Throughput Screening for Host-Directed Antimicrobials Against Intracellular Brucella | |
Kathleen Gallo, Ph.D. | Mixed Lineage Kinase 3 Inhibitors for Glioblastoma | |
Jian Hu, Ph.D. | Developing Cell-based High Throughput Screening to Identify Inhibitors Against Pathogenic Fungal ZIP Metal Transporters | |
Kin Sing Stephen Lee, Ph.D. | Developing a sHE inhibitor with Improved Physicochemical Properties and CNS Penetration for Lupus | |
Jeffrey MacKeigan, Ph.D | Small Molecule Inhibitors of ULK1 | |
Aaron Odom, Ph.D. /Jetze Tepe, Ph.D. | Exploration of in vivo Efficacy of Proteasome Inhibitors with Alternative Mechanisms | |
Bryan Smith, Ph.D. | Marophage-selective Nanotherapy to Treat Breast Cancer | |
5/19 | Robert Abramovitch, Ph.D. | Development of New Mycobacterium tuberculosis MmpL3 Inhibitors |
Bryan Copple, Ph.D. | Modulation of Macrophage Phenotype to Treat Liver Fibrosis and Cirrhosis | |
Andrea Doseff, Ph.D. / Karen Liby, Ph.D. | Identifying Novel Strategies for the Treatment of Triple Negative Breast Cancer | |
Erika Lisabeth, Ph.D. | Identification of Small Molecule Modulators of the Serum Response Factor | |
Dohun Pyeon, Ph.D. | Developing Chemokine-based Novel Immunotherapies | |
Christopher Waters, Ph.D. | Identifying Triclosan Analogs That Improve Synergy with Tobramycin to Eradicate Biofilms | |
9/17 | Susan Conrad, Ph.D. | Identifying Novel Strategies for Endocrine-resistant Metastatic ER+ Breast Cancer |
Aaron Odom, Ph.D. / Jetze Tepe, Ph.D. | Exploration of Viability of Proteasome Inhibitors with Alternative Mechanisms | |
Chrisopher Waters, Ph.D. | Identifying Compounds That Enhance Biocide Killing of Waters System Biofilms | |
Stephanie Watts, Ph.D. | 5-HT7 Receptor Drug Discovery for Cardiovascular Disease | |
Yong-Hui Zheng, Ph.D. | High Throughput Screening of Novel Anti-HIV-1 Compounds | |
1/17 | Robert Abramovitch Ph.D. | Medicinal Chemistry Optimizations of Lead Compounds That Inhibit M. tuberculosis Persistence and drug tolerance |
Andre Bachmann Ph.D. | Synthesis of Biological Evaluation of Phaseolotoxin-inspired ODC Inhibitors | |
Jon Kaguni Ph.D. | Targeted Drug Discovery to Identify Inhibitors of Bacterial DNA Replication | |
Hao-Min Kuo Ph.D. | Hyperphosphorylated tau Aggregation modulators as Candidates for Alzheimer's disease Therapeutics and Risk Factors | |
Karen Liby, Ph.D. | Synthesis and Characterization of New Rexinoids | |
Jetze Tepe, Ph.D. | Development of Drug-like TCH-165 Derivatives |